Bavarian Nordic’s mpox vaccine, Jynneos (MVA-BN), is set to be trialled in pregnant and breastfeeding women and infants. The Phase III trial (PregInPoxVac) will enrol around 350 pregnant women and 250 ...

The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children 2-11 years ...

An initial 899,000 vaccine doses have been allocated for 9 countries across Africa that have been hit hard by the current mpox surge, the WHO and other health organisations said on Wednesday.

The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always ...

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety between teenagers and adults in an NIH study.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(Reuters) -The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...